Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.2, 2011-01, pp. : 155-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite

Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies

By Greenberg Peter L.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 91-96

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Immunosuppressive Therapy for Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3184-3189

Bentham Science Publishers

Access to resources Recommend Favorite

Tipifarnib effective oral therapy for myelodysplastic syndromes

Inpharma, Vol. 1, Iss. 1477, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite